Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2021 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights

Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Lyell...
September 08, 2021 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...
August 12, 2021 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights

Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trialsCash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021...
June 16, 2021 21:49 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients...